Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two products: - **Vitablue** is not a recognized pharmaceutical or supplement with standardized composition in major drug databases as of June 2025. It may refer to a dietary supplement or multivitamin product, but no authoritative information on its ingredients, manufacturer, or regulatory status could be found. - **Lovaza** is an FDA-approved prescription medication containing omega-3-acid ethyl esters (primarily eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) derived from fish oil. It is used as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL). The mechanism involves decreasing hepatic production of triglycerides and increasing their clearance from plasma[2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitablue + lovaza.